Jazz Pharmaceuticals Reports Acquisition of Redx Pharma’s KRAS Inhibitor Program
Shots:
- Jazz Pharmaceuticals has entered into a definitive agreement with Redx Pharma to acquire the latter’s KRAS inhibitor program incl. G12D selective and pan-KRAS molecules. Jazz will perform clinical, regulatory, manufacturing & commercialization activities
- As per the agreement, Redx will obtain $10M upfront for the rights, patents & title for KRAS inhibitor programs, a payment of $870M on achieving development, regulatory & commercial milestones with an additional milestone of IND clearance plus tiered, mid-single-digit percentage sales-based royalties
- Under a separate collaboration agreement, Redx will obtain payment for research and preclinical development for completing IND-enabling studies of both KRAS programs
Ref: Jazz Pharmaceuticals | Image: Jazz Pharmaceuticals
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
